资讯
T. Rowe Price (TROW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果